Akari Therapeutics Reports Third Quarter 2019 Financial Results And Highlights Recent Clinical Progress

Posted in Biotech

November 04, 2019 • 2 min read

​Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced financial results for the third quarter ended September 30, 2019 and recent clinical progress....

Acasti Pharma Partners with Aker BioMarine to Supply Krill Oil for CaPre

Posted in Biotech

November 04, 2019 • 2 min read

Acasti Pharma Inc. (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that it has partnered with Aker BioMarine to deliver krill oil to Acasti, under a two-year, fixed price supply agreement. ...